News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Relmada Therapeutics Files Shares Registration Statement


7/1/2014 10:04:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, July 1, 2014 /PRNewswire/ -- Camp Nine, Inc. (the "Company"), which conducts its operations through Relmada Therapeutics, Inc. ("Relmada") (OTCBB: CMPE), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed resale of shares of its common stock. The registration statement relating to these securities has been filed with the SEC, but has yet to become effective.

"The filing of the shares registration statement marks a significant progress in our plan to provide liquidity for our investors and an important step ahead in the process of up-listing to a major stock exchange as soon as it will be feasible," said Sergio Traversa, CEO of the Company.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The Company recently announced that it has completed equity capital raises totaling gross proceeds of $28MM associated with a going-public transaction. Relmada went public via a reverse merger with the Company pursuant to a share exchange agreement dated May 20, 2014 whereby the Company acquired approximately 94% of the outstanding shares of Relmada.

About Relmada Therapeutics Inc./Camp Nine, Inc.

The Company, through its majority owned subsidiary Relmada, is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

The Company is currently developing LevoCap ER, its abuse resistant, once--a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine and MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Camp Nine undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Visit our website at www.relmada.com

SOURCE Relmada Therapeutics, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES